Entity
  • Medigene AG

    Created in 1994
  • BETA

    Up & running (A)
    Existing signals show a regular activity
  • Social networks

    9,139
  • Activities

  • Technologies

  • Entity types

  • Location

    Lochhamer Str. 11, 82152 Planegg, Germany

    Planegg

    Germany

  • Employees

    Scale: 51-200

    Estimated: 105

  • Engaged corporates

    1
    1 0
  • Added in Motherbase

    5 months, 2 weeks ago
Description
  • Value proposition

    Living Immunotherapies

    Medigene AG (FSE: MDG1) is a leading immuno-oncology platform company dedicated to developing T-cell therapies to effectively eliminate cancer. Its end-to-end technology platform is built on multiple proprietary exclusive product development and product enhancement technologies, and allows Medigene to create best-in-class differentiated, T cell receptor engineered T cell (TCR-T) therapies for multiple solid tumor indications that are optimized for both safety and efficacy. This platform provides product candidates for both its in-house therapeutics pipeline and partnering.

    For more information, please visit www.medigene.com

    Immunotherapies and T Cell receptors TCR

Corporate interactions BETA
Corporate TypeTweets Articles
Invest in Bavaria - The Business Promotion Agency of the State of Bavaria
Invest in Bavaria - The Business Promotion Agency of the State of Bavaria
Startup accelerator & VC, Government Administration
Invest in Bavaria - The Business Promotion Agency of the State of Bavaria
Startup accelerator & VC, Government Administration
Other

13 Aug 2024


Similar entities
Loading...
Loading...
Social network dynamics